Geode Capital Management LLC Has $31.51 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Geode Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,786,671 shares of the company’s stock after acquiring an additional 378,136 shares during the period. Geode Capital Management LLC owned 1.22% of Amneal Pharmaceuticals worth $31,511,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of AMRX. Barclays PLC grew its stake in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after purchasing an additional 169,756 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $311,000. Wellington Management Group LLP bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $687,000. State Street Corp increased its holdings in Amneal Pharmaceuticals by 3.8% in the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after buying an additional 127,753 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in Amneal Pharmaceuticals during the third quarter valued at approximately $169,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. This represents a 76.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on AMRX shares. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research report on Friday, September 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Trading Up 0.8 %

NASDAQ:AMRX opened at $7.85 on Thursday. The firm has a market capitalization of $2.43 billion, a PE ratio of -11.54 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.01 and a 1 year high of $9.48. The firm’s fifty day simple moving average is $8.38 and its 200 day simple moving average is $7.96.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.